The outbreak of the 2019 novel coronavirus (SARS-CoV-2) has infected millions of people with a large number of deaths across the globe. The existing therapies are limited in dealing with SARS-CoV-2 due to the sudden appearance of the virus. Therefore, vaccines and antiviral medicines are in desperate need. We took immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein (S), membrane glycoprotein (M) and nucleocapsid protein (N) of SARS-CoV-2, followed by estimating their antigenicity and interactions with the human leukocyte antigen (HLA) alleles. Allergenicity, toxicity, physiochemical properties analysis and stability were examined to confirm the specificity and selectivity of the epitope candidates. We identified a total of five B cell epitopes in RBD of S protein, seven MHC class-I, and 18 MHC class-II binding T-cell epitopes from S, M and N protein which showed non-allergenic, non-toxic and highly antigenic features and non-mutated in 55,179 SARS-CoV-2 virus strains until June 25, 2020. The epitopes identified here can be a potentially good candidate repertoire for vaccine development.

2019年新型冠状病毒（SARS-CoV-2）的爆发已感染了全球数百万人，并造成大量死亡。由于该病毒的突然出现，现有的疗法在治疗SARS-CoV-2方面受到限制。因此，迫切需要疫苗和抗病毒药物。我们采用免疫信息学方法鉴定了SARS-CoV-2的表面糖蛋白（S），膜糖蛋白（M）和核衣壳蛋白（N）的B细胞和T细胞表位，然后评估它们的抗原性和与人类的相互作用白细胞抗原（HLA）等位基因。检查了变应原性，毒性，理化特性分析和稳定性，以确认候选抗原决定簇的特异性和选择性。我们在S蛋白的RBD中鉴定出总共五个B细胞表位，七个I类MHC，